Regenicin EBIT

As of the most recent data (September 2023), RGIN shows a EBIT of $-630K. That compares with $-620K in the prior-year period — down 1.2% year over year. That is below the Industrials sector average of $38B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RGIN's EBIT is now $-630K (was $-620K) — a 1.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Regenicin is outperforming or lagging.

The Industrials sector average EBIT is about $38B. Regenicin is at $-630K, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how RGIN stacks up against individual peers as well.

Tracking RGIN's ebit over time shows whether Regenicin is scaling, shrinking, or reshaping that part of the business. The current reading is $-630K That compares with $-620K in the prior-year period — down 1.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Regenicin's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-630K) with ownership activity and broader fundamentals.